Alicia Herrero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alicia Herrero has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Elena Villamañán
Hospital Pharmacy, Hospital Universitario La Paz, España
3 shared publications - Alejandro Balsa
Hospital Universitario La Paz, Madrid, Spain
2 shared publications - Chamaida Plasencia-Rodríguez
Rheumatology Service, Hospital Universitario la Paz-IdiPaz, Madrid, Spain
2 shared publications - Francisco Gayá
Biostatistic Department, La Paz University Hospital, Madrid, Spain
2 shared publications - Francisco Moreno Ramos
La Paz Research Institute—IdiPAZ, 28046 Madrid, Spain
2 shared publications - Inmaculada Jiménez-Nácher
Pharmacy Department, La Paz University Hospital, Madrid, Spain
2 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Elsevier in Farmacia Hospitalaria
Clinical experience with anti-interleukin-5 monoclonal antibodies in the treatment of eosinophilic granulomatosis with polyangiitis
- 14 October 2026
- Published by Elsevier in Farmacia Hospitalaria
Open AccessClinical experience with anti-interleukin-5 monoclonal antibodies in the treatment of eosinophilic granulomatosis with polyangiitis
- Open Access
- 1 October 2026
- Published by Qeios Ltd
Review of: "The Pauli Spin Algebra, Related Clifford Algebra Representation, and the Derivation of the Dirac Hamiltonian Operator"
The same report applies since I already accessed the new version.
- 1 October 2026
- Published by Qeios Ltd
Open AccessReview of: "The Pauli Spin Algebra, Related Clifford Algebra Representation, and the Derivation of the Dirac Hamiltonian Operator"
The same report applies since I already accessed the new version.
- Open Access
- 29 September 2026
- Published by Qeios Ltd
Review of: "The Pauli Spin Algebra, Related Clifford Algebra Representation, and the Dirac Hamiltonian Operator Derivation"
General assessment The manuscript proposes an algebraic derivation of the Dirac Hamiltonian starting from the Pauli spin algebra, Clifford-algebra representations, and second-quantized Fock-space structures. The general idea is interesting, and an al...
- 29 September 2026
- Published by Qeios Ltd
Open AccessReview of: "The Pauli Spin Algebra, Related Clifford Algebra Representation, and the Dirac Hamiltonian Operator Derivation"
General assessment The manuscript proposes an algebraic derivation of the Dirac Hamiltonian starting from the Pauli spin algebra, Clifford-algebra representations, and second-quantized Fock-space structures. The general idea is interesting, and an al...
- 26 January 2023
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 16 (3) , 213-226
Development of a telematic pharmaceutical care app (Haemoassist) for multidisciplinary follow-up of patients with congenital coagulopathies
Guidelines for congenital coagulopathies recommend that patients record treatment administrations and bleeding episodes to help healthcare professionals monitor the disease.We studied over two year...
- 26 January 2023
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 16 (3) , 213-226
Development of a telematic pharmaceutical care app (Haemoassist) for multidisciplinary follow-up of patients with congenital coagulopathies
Guidelines for congenital coagulopathies recommend that patients record treatment administrations and bleeding episodes to help healthcare professionals monitor the disease.We studied over two year...
- 1 June 2021
- Published by Elsevier in Reumatología Clínica (English Edition)
- Vol. 17 (6) , 335-342
Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price
- 1 June 2021
- Published by Elsevier in Reumatología Clínica (English Edition)
- Vol. 17 (6) , 335-342
Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price
- 1 June 2021
- Published by Elsevier in Reumatología Clínica
- Vol. 17 (6) , 335-342
Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price
- 1 June 2021
- Published by Elsevier in Reumatología Clínica
- Vol. 17 (6) , 335-342
Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price
- 10 February 2021
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 23 (6) , 937-947
Prediction of thromboembolic events and mortality by the CHADS2 and the CHA2DS2-VASc in COVID-19
Aims: Age, sex, and cardiovascular disease have been linked to thromboembolic complications and poorer outcomes in COVID-19. We hypothesize that CHADS2 and CHA2DS2-VASc scores may predict thromboembolic events and mortality in COVID-19. Methods and results: COVID-19 hospitalized patients with confirmed SARS-CoV-2 infection from 1 March to 20 April 2020 who completed at least 1-month follow-up or died were studied. CHADS2 and CHA2DS2-VASc scores were calculated. Given the worse prognosis of male patients in COVID-19, a modified CHA2DS2-VASc score (CHA2DS2-VASc-M) in which 1 point was given to male instead of female was also calculated. The associations of these scores with laboratory results, thromboembolic events, and death were analysed. A total of 3042 patients (mean age 62.3 ± 20.3 years, 54.9% male) were studied and 115 (3.8%) and 626 (20.6%) presented a definite thromboembolic event or died, respectively, during the study period [median follow 59 (50–66) days]. Higher score values were associated with more marked abnormalities of inflammatory and cardiac biomarkers. Mortality was significantly higher with increasing scores for CHADS2, CHA2DS2-VASc, and CHA2DS2-VASc-M (P < 0.001 for trend). The CHA2DS2-VASc-M showed the best predictive value for mortality [area under the receiver operating characteristic curve (AUC) 0.820, P < 0.001 for comparisons]. All scores had poor predictive value for thromboembolic events (AUC 0.497, 0.490, and 0.541, respectively). Conclusion: The CHADS2, CHA2DS2-VASc, and CHA2DS2-VASc-M scores are significantly associated with all-cause mortality but not with thromboembolism in COVID-19 patients. They are simple scoring systems in everyday use that may facilitate initial ‘quick’ prognostic stratification in COVID-19.
- 10 February 2021
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 23 (6) , 937-947
Prediction of thromboembolic events and mortality by the CHADS2 and the CHA2DS2-VASc in COVID-19
Aims: Age, sex, and cardiovascular disease have been linked to thromboembolic complications and poorer outcomes in COVID-19. We hypothesize that CHADS2 and CHA2DS2-VASc scores may predict thromboembolic events and mortality in COVID-19. Methods and results: COVID-19 hospitalized patients with confirmed SARS-CoV-2 infection from 1 March to 20 April 2020 who completed at least 1-month follow-up or died were studied. CHADS2 and CHA2DS2-VASc scores were calculated. Given the worse prognosis of male patients in COVID-19, a modified CHA2DS2-VASc score (CHA2DS2-VASc-M) in which 1 point was given to male instead of female was also calculated. The associations of these scores with laboratory results, thromboembolic events, and death were analysed. A total of 3042 patients (mean age 62.3 ± 20.3 years, 54.9% male) were studied and 115 (3.8%) and 626 (20.6%) presented a definite thromboembolic event or died, respectively, during the study period [median follow 59 (50–66) days]. Higher score values were associated with more marked abnormalities of inflammatory and cardiac biomarkers. Mortality was significantly higher with increasing scores for CHADS2, CHA2DS2-VASc, and CHA2DS2-VASc-M (P < 0.001 for trend). The CHA2DS2-VASc-M showed the best predictive value for mortality [area under the receiver operating characteristic curve (AUC) 0.820, P < 0.001 for comparisons]. All scores had poor predictive value for thromboembolic events (AUC 0.497, 0.490, and 0.541, respectively). Conclusion: The CHADS2, CHA2DS2-VASc, and CHA2DS2-VASc-M scores are significantly associated with all-cause mortality but not with thromboembolism in COVID-19 patients. They are simple scoring systems in everyday use that may facilitate initial ‘quick’ prognostic stratification in COVID-19.